S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
TAMPA - TuHURA Biosciences, Inc. (NASDAQ:HURA), a Phase 3 immune-oncology company, has been added to the Russell 3000 and Russell 2000 indexes as part of the 2025 annual reconstitution, effective June 27, 2025. The company, currently valued at $97 million, has seen its shares decline 64.6% over the past year, according to InvestingPro data.
The company, which develops technologies to overcome resistance to cancer immunotherapy, joined the indexes in its first year as a publicly traded entity.
"The inclusion of TuHURA in the Russell indexes highlights the significant progress we have made in TuHURA’s first year as a publicly traded company," said James Bianco, President and Chief Executive Officer of TuHURA Biosciences, according to the press release.
TuHURA is currently enrolling patients in a Phase 3 trial of IFx-2.0 as an adjunctive therapy to Keytruda for first-line treatment of advanced or metastatic Merkel cell carcinoma. The company also plans to advance an anti-VISTA antibody into a Phase 2 clinical trial for NMPL1-mutated Acute Myeloid Leukemia following its acquisition of Kineta, Inc.
The Russell 3000 Index tracks the performance of the largest 3,000 U.S. stocks by market capitalization. Membership in this index, which is recalculated annually, includes automatic inclusion in either the large-cap Russell 1000 Index or small-cap Russell 2000 Index.
Russell indexes serve as benchmarks for investment strategies, with over $10 trillion in assets benchmarked against Russell’s U.S. Indexes. The indexes are part of FTSE Russell, a global index provider.
In other recent news, TuHURA Biosciences has completed its acquisition of Kineta, Inc., incorporating a Phase 2 ready VISTA inhibiting monoclonal antibody into its immuno-oncology pipeline. This acquisition involves the issuance of approximately 2.87 million TuHURA shares and potential future considerations. The company plans to initiate a Phase 2 trial with the newly acquired drug candidate, TBS-2025, in combination with a menin inhibitor for acute myeloid leukemia by the second half of 2025. Additionally, TuHURA has initiated a Phase 3 trial of its lead drug, IFx-2.0, for patients with advanced Merkel cell carcinoma, conducted under a Special Protocol Assessment with the FDA. This trial aims to evaluate IFx-2.0 as an adjunctive therapy alongside Keytruda, with the primary endpoint being the objective response rate. In light of these developments, H.C. Wainwright has reiterated a Buy rating with a $12 price target for TuHURA, while Brookline Capital Markets initiated coverage with a Buy rating and a $9 price target. The merger between TuHURA and Kineta was also approved by stockholders, with the companies expecting to finalize the merger soon. These strategic moves are part of TuHURA’s efforts to expand its pipeline and address resistance to cancer immunotherapy.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.